BOAN BIOTECH (06955) Surges Over 6% as Denosumab Injection Gains Approval in Bolivia, Plans to Submit Marketing Applications in Multiple Countries

Stock News01-13

BOAN BIOTECH (06955) rose more than 6%. At the time of writing, the stock was up 6.28%, trading at HKD 9.98, with a turnover of HKD 49.8845 million. On the news front, on January 11, BOAN BIOTECH announced that its board of directors was pleased to announce that its self-developed Denosumab Injection (60mg) (R&D code: BA6101) had received marketing approval from the Bolivian National Agency for Medicines and Health Technologies (AGEMED). BA6101 is a biosimilar to the originator reference drug Prolia®, which is widely used globally for the treatment of osteoporosis. The indications for BA6101 are identical to those of the originator reference drug. BA6101 was developed based on the company's global R&D strategy and is planned for commercialization in numerous countries and regions worldwide. Currently, the Marketing Authorisation Application for BA6101 in the United Kingdom is under review, and the company plans to submit marketing applications in Europe, the United States, Japan, and other countries and regions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152800548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152800548","market":"sg","top_or_hot":-1,"title":"BOAN BIOTECH (06955) Surges Over 6% as Denosumab Injection Gains Approval in Bolivia, Plans to Submit Marketing Applications in Multiple Countries","media":"Stock News","content":"<p>BOAN BIOTECH (06955) rose more than 6%. At the time of writing, the stock was up 6.28%, trading at HKD 9.98, with a turnover of HKD 49.8845 million.\nOn the news front, on January 11, BOAN BIOTECH announced that its board of directors was pleased to announce that its self-developed Denosumab Injection (60mg) (R&D code: BA6101) had received marketing approval from the Bolivian National Agency for Medicines and Health Technologies (AGEMED).\nBA6101 is a biosimilar to the originator reference drug Prolia®, which is widely used globally for the treatment of osteoporosis.\nThe indications for BA6101 are identical to those of the originator reference drug.\nBA6101 was developed based on the company's global R&D strategy and is planned for commercialization in numerous countries and regions worldwide.\nCurrently, the Marketing Authorisation Application for BA6101 in the United Kingdom is under review, and the company plans to submit marketing applications in Europe, the United States, Japan, and other countries and regions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOAN BIOTECH (06955) Surges Over 6% as Denosumab Injection Gains Approval in Bolivia, Plans to Submit Marketing Applications in Multiple Countries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOAN BIOTECH (06955) Surges Over 6% as Denosumab Injection Gains Approval in Bolivia, Plans to Submit Marketing Applications in Multiple Countries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-13 10:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BOAN BIOTECH (06955) rose more than 6%. At the time of writing, the stock was up 6.28%, trading at HKD 9.98, with a turnover of HKD 49.8845 million.\nOn the news front, on January 11, BOAN BIOTECH announced that its board of directors was pleased to announce that its self-developed Denosumab Injection (60mg) (R&D code: BA6101) had received marketing approval from the Bolivian National Agency for Medicines and Health Technologies (AGEMED).\nBA6101 is a biosimilar to the originator reference drug Prolia®, which is widely used globally for the treatment of osteoporosis.\nThe indications for BA6101 are identical to those of the originator reference drug.\nBA6101 was developed based on the company's global R&D strategy and is planned for commercialization in numerous countries and regions worldwide.\nCurrently, the Marketing Authorisation Application for BA6101 in the United Kingdom is under review, and the company plans to submit marketing applications in Europe, the United States, Japan, and other countries and regions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"","article_id":"1152800548","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152800548","pubTimestamp":1768270823,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BOAN BIOTECH (06955) rose more than 6%. At the time of writing, the stock was up 6.28%, trading at HKD 9.98, with a turnover of HKD 49.8845 million. On the news front, on January 11, BOAN BIOTECH...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06955":"博安生物","BK1161":"生物科技"},"translate_title":"博安生物(06955)大涨超6%，地诺塞单抗注射液获玻利维亚批准，拟在多国递交上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1},"content_text":"BOAN BIOTECH (06955) rose more than 6%. At the time of writing, the stock was up 6.28%, trading at HKD 9.98, with a turnover of HKD 49.8845 million.\nOn the news front, on January 11, BOAN BIOTECH announced that its board of directors was pleased to announce that its self-developed Denosumab Injection (60mg) (R&D code: BA6101) had received marketing approval from the Bolivian National Agency for Medicines and Health Technologies (AGEMED).\nBA6101 is a biosimilar to the originator reference drug Prolia®, which is widely used globally for the treatment of osteoporosis.\nThe indications for BA6101 are identical to those of the originator reference drug.\nBA6101 was developed based on the company's global R&D strategy and is planned for commercialization in numerous countries and regions worldwide.\nCurrently, the Marketing Authorisation Application for BA6101 in the United Kingdom is under review, and the company plans to submit marketing applications in Europe, the United States, Japan, and other countries and regions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152800548","isCrawlerRequest":true}